Accumulation of gamma-globin mRNA and induction of erythroid differentiation after treatment of human leukaemic K562 cells with tallimustine.
Human leukaemic K562 cells can be induced in vitro to erythroid differentiation by a variety of chemical compounds, including haemin, butyric acid, 5-azacytidine, cytosine arabinoside, mithramycin and chromomycin, cisplatin and cisplatin analogues. Differentiation of K562 cells is associated with an increase of expression of embryo-fetal globin genes, such as the zeta-, epsilon- and gamma-globin genes. The K562 cell line has been proposed as a very useful in vitro model system to determine the therapeutic potential of new differentiating compounds as well as to study the molecular mechanism(s) regulating changes in the expression of embryonic and fetal human globin genes. Inducers of erythroid differentiation stimulating gamma-globin synthesis could be considered for possible use in the therapy of haematological diseases associated with a failure in the expression of normal beta-globin genes. We have analysed the effects of tallimustine and distamycin on cell growth and differentiation of K562 cells. The results demonstrated that tallimustine is a potent inducer, while distamycin is a weak inducer, of K562 cell erythroid differentiation. Erythroid differentiation was associated with an increase of accumulation of gamma-globin mRNA and of production of both haemoglobin (Hb) Gower 1 and Hb Portland. In addition, tallimustine-mediated erythroid induction occurred in the presence of activation of the apoptotic pathway. The reasons for proposing tallimustine as an inducer of gamma-globin gene expression are strongly sustained by the finding that this compound stimulates fetal haemoglobin production in human erythroid precursor cells from normal subjects.
Bianchi
N
N
Department of Biochemistry and Molecular Biology, University of Ferrara, Italy.
Chiarabelli
C
C
Borgatti
M
M
Mischiati
C
C
Fibach
E
E
Gambari
R
R
D017209:Apoptosis; D015152:Blotting, Northern / Q000379:methods; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division; D003561:Cytarabine / Q000627:therapeutic use; D004268:DNA-Binding Proteins / Q000627:therapeutic use*; D004214:Distamycins / Q000737:chemistry / Q000627:therapeutic use*; D004912:Erythrocytes / Q000502:physiology*; D005319:Fetal Hemoglobin / Q000096:biosynthesis; D005914:Globins / Q000235:genetics*; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006454:Hemoglobins / Q000096:biosynthesis; D006801:Humans; D006918:Hydroxyurea / Q000494:pharmacology; D020014:K562 Cells; D009588:Nitrogen Mustard Compounds / Q000737:chemistry / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction
D004268:DNA-Binding Proteins; D004214:Distamycins; D006454:Hemoglobins; D009588:Nitrogen Mustard Compounds; D012333:RNA, Messenger; D003561:Cytarabine; C066900:tallimustine; C030000:stallimycin; D005914:Globins; D005319:Fetal Hemoglobin; D006918:Hydroxyurea